Briefing
Optimizing oligometastatic disease management with circulating tumor DNA: a correlative analysis from the phase II randomized EXTEND trial
ESTRO 2026 abstract 846 (Sherry first, Tang last) is a correlative ctDNA analysis of the phase 2 randomized EXTEND trial. Title, authorship, DOI, and pagination were verified on CrossRef; the abstract body was not deposited, so no ESTRO-only numeric results are filed. Exploratory ctDNA findings are taken from the subsequent JCO paper (PMID 42142259), not from institutional news releases.